Highnoon Laboratories Limited

HINOON

PK0070701013

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 03:30:00 24/05/2024 am IST			5-day change	1st Jan Change
670.9 ^PKR	+1.60%		-1.19%	+32.96%

29/04	Highnoon Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
09/04	Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highnoon Laboratories Limited Appoints Romesh Elapata as Director

August 31, 2018

On EGM held on August 30, 2018, the Highnoon Laboratories Limited appointed Romesh Elapata as director of the company.

Latest news about Highnoon Laboratories Limited

Highnoon Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2023	09/04	CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30/23/30	CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/23/30	CI
Highnoon Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	02/23/02	CI
Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2022	14/23/14	CI
Highnoon Laboratories Limited Announces Director Changes, Effective February 24, 2023	23/23/23	CI
Highnoon Laboratories Limited Announces Executive Changes	23/22/23	CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	31/22/31	CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	26/22/26	CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	22/21/22	CI
Highnoon Laboratories Limited Appoints Adeel Abbas Haider as Chief Executive Officer	09/21/09	CI
Highnoon Laboratories Limited Appoints Tauseef Ahmad Khan as Chairman	09/21/09	CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021	12/21/12	CI
Highnoon Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2021	29/21/29	CI
Highnoon Laboratories Limited Recommends Final Cash Dividend for the Year Ended December 31, 2020	25/21/25	CI
Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2020	25/21/25	CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	26/20/26	CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter Ended June 30, 2020	24/20/24	CI
Highnoon Laboratories Limited Reports Earnings Results for the First Quarter Ended March 31, 2020	01/20/01	CI
Creso Pharma Limited Announces a Collaboration with Highnoon Laboratories Limited and Route2 Health Limited	14/20/14	CI
Highnoon Laboratories Limited Recommends Final Cash Dividend for the Year Ended December 31, 2019	31/20/31	CI
Highnoon Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2019	31/20/31	CI
Highnoon Laboratories Limited Reports Earnings Results for the Third Quarter Ended September 30, 2019	29/19/29	CI
Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter Ended June 30, 2019	26/19/26	CI

Chart Highnoon Laboratories Limited

Duration

Period

More charts

Highnoon Laboratories Limited is a Pakistan-based company that is engaged in the manufacturing, importing, selling and marketing of pharmaceutical and allied consumer products. The Company's product categories include cardiology, metabolic, gastroenterology, musculoskeletal, anti-infective, obstetrics and gynecology, pediatrics, allergy, respiratory, and urology. Its cardiology products include Somno, Hitica, Apiban, Pidogrel-AP, Blokium DIU, Epliron, Sacuvia, Ivaset, Rivaro, Valforge and Herbesser. Its metabolic products include Xormet XR, MetFormin HCI, Diajard-MXR, Diajard-M and Diajard. The Company's gastroenterology products include Liv 52, Rabecid and Racedo. Its musculoskeletal products include Flexa Plus, Airtal ER and Tamadol. The Company's pediatric products include Bonisan, Cogniza, Flu Ace, Prospan and Tres Orix Forte. Its allergy products include Leviva and Kestine. Its Respiratory products include Combivair Forte, Sprahaler Respules, Foracort HFA Inhaler and Rotaflo.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HIGHNOON LABORATORIES LIMITED	+32.96%	13Cr
ELI LILLY AND COMPANY	+38.51%	73TCr
NOVO NORDISK A/S	+33.05%	60TCr
JOHNSON & JOHNSON	-6.23%	35TCr
MERCK & CO., INC.	+18.78%	33TCr
ABBVIE INC.	+1.35%	28TCr
ASTRAZENECA PLC	+16.00%	24TCr
NOVARTIS AG	+8.09%	20TCr
ROCHE HOLDING AG	-5.77%	20TCr
AMGEN INC.	+6.19%	16TCr